There is a broad consensus that proteomics will play a central role in driving the future of drug development and biomarker discovery. However, despite its potential, proteomics has yet to become ubiquitous, chiefly constrained by the tools’ high costs, inflexible analysis, and lack of interoperable, quantitative data.

In this webinar, experts from Nomic will unveil novel solutions designed to unlock proteomics at scale, including a high-throughput, proteome-wide panel capable of measuring 1000 proteins simultaneously. Leading researchers from the University of Pennsylvania and the University of California, Los Angeles, will share case studies that demonstrate how these tools are helping scientists dig deeper into oncology and autoimmune disease:

• Milad Dagher, PhD, Nomic CEO, will introduce Nomic’s technology and reveal how the company is dramatically expanding its content and evolving its product portfolio to support a broader range of applications.
• Allie Greenplate, PhD, University of Pennsylvania, will highlight her research leveraging Nomic’s solutions for the discovery and validation of biomarkers from plasma biobank samples, accelerating insights into autoimmune diseases.
• Alice Soragni, PhD, University of California, Los Angeles, will discuss how Nomic’s high-throughput capabilities support her efforts to personalize cancer therapy, leveraging her drug screening platform based on patient-derived tumor organoids.
• Narges Rashidi, PhD, Nomic, will present a first look at Nomic’s large-scale cell perturbation study powered by nELISA^®—designed to fuel the next generation of AI-driven drug discovery.